SACRAMENTO, Calif., May 4, 2026, 14:00 PDT
Lunai Bioworks Inc. has wrapped up a $20 million preferred-stock deal, securing CNS drug-delivery and neurotherapeutic IP in an effort to broaden its brain-disease lineup. The move, finalized May 1, also bolsters its case for Nasdaq equity compliance. Lunai disclosed the acquisition Monday.
Timing is critical here. Lunai faces a Nasdaq hearings panel following previous delisting pressure. The company says its early accounting and fair-value review put stockholders’ equity above the $2.5 million threshold for keeping its Nasdaq Capital Market spot. Nasdaq rules also demand that primary equity shares stay at or above a $1 minimum bid price.
Lunai was last quoted at $0.3246 as of 1:45 p.m. PDT, with shares swinging between $0.43 and $0.2857 earlier in the session. Roughly 99.1 million shares had changed hands by that point. The company’s market cap hovered near $7.6 million—falling short of the declared value for the preferred stock involved in the deal.
This wasn’t a cash raise. According to an SEC filing, Lunai issued eight Series B convertible preferred shares, putting the total stated value at $20 million, as part of the merger consideration for Neurobridge IP Holdings. Of those, Oncotelic Inc. picked up five preferred shares valued at $12.5 million, while Pelerin Therapeutics Inc. took three preferred shares, with a stated value of $7.5 million.
According to the filing, Neurobridge owned nothing but its patents and pending applications. No staff, no customer base, not even a sales or distribution network. It operated without facilities, trade names, or any businesses bringing in revenue. Lunai added that there was no cash changing hands in the deal.
The portfolio Lunai picked up covers patents related to Alzheimer’s compounds, anti-TGF-beta agents, various apomorphine formulations, plus intranasal delivery tech targeting neurological conditions. Lunai described the additions as bringing in two key delivery options: one, a prodrug platform designed to cross the blood-brain barrier; the other, a nose-to-brain method intended to shuttle drugs via nasal passages instead of relying on the bloodstream. That barrier acts as a defensive shield for the brain—useful, but it creates a challenge for getting many therapies where they need to go.
Chief Executive David Weinstein called it a combination of “complementary CNS delivery approaches,” and said the deal targets “persistent challenges in neurological drug development.” PR Newswire
The company pointed to the patents as potential backing for Alzheimer’s projects, combo therapies, and maybe even 505(b)(2) regulatory filings—the U.S. track for tweaked or repurposed drugs. Lunai also linked the IP to CNS biodefense countermeasures, noting that quick delivery into the brain could be central to the approach.
Common shareholders are still staring down a capital-structure overhang. Series B preferred stock comes with the option to convert into up to 13,333,333 common shares at $1.50 each, but that’s only possible if stockholders sign off first. Lunai said that approval isn’t on the agenda for the May 8 special meeting—unless the company ends up filing a separate proxy supplement.
The deal doesn’t put the listing questions to rest. Lunai warned Nasdaq could still rule that the company falls short on the stockholders’ equity front, adding that preferred stock might be accounted for differently than management hopes. The filing also highlighted a few other headaches—namely, the unresolved $1 bid-price hurdle, looming delisting threats, and the chance that the acquired patents end up invalid, unenforceable, or don’t carry much commercial weight.
Lunai wants shareholders to sign off on a reverse split, anywhere from 1-for-3 up to 1-for-30, but the board will call the final ratio. Their pitch: boosting the share price to protect the Nasdaq slot. Even so, management cautioned that a split might not be enough to keep the stock above the minimum.
CNS drug delivery isn’t short on competition or complexity. Denali Therapeutics pitches its TransportVehicle platform for ferrying treatments past the blood-brain barrier. Roche, for its part, has Brainshuttle in clinical trials. BioArctic frames its BrainTransporter approach as enabling antibodies and other big molecules to access the brain.
Lunai remains in its early stages. According to its most recent annual report, operations run through Renovaro Biosciences, Renovaro Cube, and BioSymetrics. No product sales revenue yet. The company flagged a need for further financing and cautioned that profitability might never be reached.
